An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-Operative Oncology Group

Anticancer Research

Volumn 21, Issue 4 B, 2001, Pages 3005-3010

  Pectasides, D ^a   Kalofonos, H P ^a   Samantas, E ^a   Nicolaides, C ^a   Papacostas, P ^a   Onyenadum, A ^a   Visvikis, A ^a   Skarlos, D ^a   Fountzilas, G ^a  

^a Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Gencitabine; NSCLC; Salvage chemotherapy; Vinorelbine

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GROWTH INHIBITION; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; OUTPATIENT; PAIN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; GRANULOCYTE COLONY-STIMULATING FACTOR; GREECE; HUMANS; IFOSFAMIDE; LIFE TABLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEUTROPENIA; PACLITAXEL; PALLIATIVE CARE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0035160669     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Management strategies for recurrent non-small cell lung cancer
3. Gemcitabine as second-line treatment for advanced non-small cell lung cancer. A phase II trial
4. Salvage therapy with gemcitabine in advanced non-small lung cancer (NSCLC) progressing after prior carboplatin- paclitaxel
5. Efficacy and toxicity profile of gemcitabine in previously treated patients with non-small cell lung cancer (NSCLC)
6. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second line therapy in patients with advanced non-small cell lung cancer
7. Phase II studies of gemcitabine for non-small cell lung cancer in Japan
8. Single-agent gemcitabine as second-line treatment in patients with advanced non-small cell lung cancer
9. Cisplatin-carboplatin-gemcitabine or ifosfamide-gemcitabine in advanced non-small cell lung carcinoma: Two pilot studies
10. Failure of vinorelbine produce responses in pretreated non-small cell lung cancer patients
11. Vinorelbine (VNB) as single agent in the treatment of advanced non-small cell lung cancer (NSCLC)
12. Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens
13. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer
14. Summary of data form in vitro and phase I vinorelbine (navelbine) studies
15. A phase I clinical, plasma and cellular pharmacology study of gemcitabine
16. Maximum tolerated dose defined for single agent gemcitabine. A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small cell lung cancer
17. Gemcitabine plus vinorelbine in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). A phase II study
18. A feasibility study of vinorelbine (VNR) and gemcitabine in inoperable stage IIIB-IV NSCLC
19. Phase II multicenter trial with gemcitabine and vinorelbine in patients with advanced (stage IIIB, IV) non-small cell lung cancer
20. A multi-center phase II study of gemcitabine (GEM) and vinorelbine (VRN) in patients with advanced stage IIIB-IV non-small cell lung cancer
21. Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): A phase I trial
22. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with non-small cell lung cancer
23. Completed phase II multicenter trial with gemcitabine and vinorelbine in patients with advanced (stage IIIB and IV) non-small cell lung cancer (NSCLC)
24. Phase II trial of Gemzar and navelbine in the treatment of patients with stage IIIB and IV nonsmall cell lung cancer
25. Vinorelbine/gemcitabine in advanced non-small cell lung cancer. Final results of an AASLC trial
26. WHO Handbook for Reporting Results of Cancer Treatment
27. Non-parametric estimation for incomplete observations
28. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer
29. Gemcitabine as single agent in the treatment of elderly patie with advanced non-small cell lung cancer
30. New triplet chemotherapy combination with carboplatin paclitaxel and gemcitabine plus amifostine support in advanced non-small ce,ll lung cancer
31. Combination gemcitabine and vinorelbine in the second line treatment of non-small cell lung cancer (NSCLC). A phase II study of the Minnie Pearl Cancer Research Network
32. A phase II study of gemcitabine and vinorelbine salvage chemotherapy for taxanes nonsmall cell lung cancer (NSCLC)
33. Phase II study of combination gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer
34. Effective salvage treatment for metastatic non-small cell lung cancer (NSCLC). Combination of gemcitabine, vinorelbine and cis-platin (GVC)
35. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum based chemotherapy